IBCD

29 - 30 November 2018 Brussels, Belgium

www.eortc.org/ibcd

#IBCD2018

First-in-class regulatory science

INVITATION TO INDUSTRY

KEY DATES IBCD 29 - 30 November 2018 Registration opening 17 May 2018 (10 AM CET) Early Registration 17 May - 16 August 2018 (10 AM CEST) Late Registration 16 August - 15 November 2018 (10 AM CET)

VENUE Radisson Blu Royal Hotel, Brussels Rue Fossé-aux-Loups 1000 Brussels, Belgium

Dear Colleagues, We are honoured to introduce you to the IBCD 2018: Innovation and Biomarkers in Cancer Drug Development conference. This is a unique joint meeting organized by the European Organisation for Research and Treatment of Cancer (EORTC), an academic research organization, the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR), a professional scientific association. In recent years, cancer drug and biomarker development and implementation in daily practice has become so complex that it requires a diverse range of expertise. The intention of IBCD 2018 is to shine a spotlight on multi-stakeholder approaches to cancer drug development with new cancer biomarkers in a scientific programme which includes input from regulators, industry, academia, patients and payers. IBCD 2018 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists endeavour to build upon the recommendations and action points decided upon at the IBCD2016-edition. Topics, such as, Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice will be addressed. The conference will also discuss the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs. We welcome your support for this meeting which will foster new forms of partnerships between academia, industry, regulatory, health technology assessment bodies and payers adding value to tomorrow’s personalized cancer treatments for patients in a daily practice setting. Denis Lacombe and Roberto Salgado, Co-chairs

1. IBCD IN A NUTSHELL IBCD welcomed 178 participants in 2016.

Delegate status

Delegates status Academic

Delegate status

Biotech/Technology/Diagnostic Media

Academic Biotech/Technology/Diagnostic

EuropeanMedia Bodies

European Bodies

Foundation Foundation

Governmental Institutions

Governmental Industry Institutions Patient/Patient advocacy

Industry Regulators

Patient/Patient advocacy Regulators

Delegates participation by continent Delegates participation by country

Oceania Europe Asia North America

2. GRANTS The provision of Education Grants help to provide the most appropriate setting for participants to learn about the evolving scientific, methodological and regulatory environment for drug and biomarker development. The grants support the meeting facilities and operational activities, helping to provide the most appropriate setting for participants to establish new approaches translating clinical trial data into daily practice, as well as networking and holding discussions with their peers, etc. This is a major aid and advancement to the quality and impact of the scientific programme. Your support will be acknowledged on the conference website and in the programme book.

3. SPONSORING Increase your brand recognition promoting your company to a targeted audience and become an IBCD partner!

PARTNER SUPPORT PACKAGE Major Sponsor (20 000 Euros) Acknowledgment on the conference website and in the promotional material Three complimentary registrations for the meeting Sponsor (15 000 Euros) Acknowledgment on the conference website and in the promotional material Two complimentary registrations for the meeting Contributor (10 000 Euros) Acknowledgment on the conference website and in the promotional material One complimentary registration for the meeting   Supporter (5 000 Euros) Acknowledgment on the conference website and in the promotional material

SPONSORSHIP OPPORTUNITIES Networking • Coffee Breaks 6 000 euros • Lunch Break 10 000 euros Breaks will allow delegates to talk to each other. Breaks will be the perfect moment to present the activites of your company. A roll up branded will be placed in the networking room. Advertisement • Lanyards 1 000 euros Be the sponsor and guarantee your visibility during the whole congress (logo placed on the lanyard). Limited to 1 sponsor. • Pens and Notepads 1 000 euros Advertising opportunity ensuring visibility for your company. Limited to 1 sponsor. Costs production are not included. Educational • Webcasts 9 000 euros Webcasts will be available on the conference website after the event. The company will be acknowledged on the webcasts web page.

4. SCIENTIFIC PROGRAMME 2016 The previous IBCD programme is available on the 2016 conference website www.eortc.org/ibcd2016 THURSDAY 8 SEPTEMBER 2016 09.00

Welcome

09.30

Session 1 “QA & QC from pre analytical steps to clinical utility”

11.00

Coffee Break

11.30

Session 2 “Considerations in assay development and its integration into drug development: Clinical trials and beyond into clinical practice”

13.00

14.00

Lunch Break

Session 3 “Patient access and regulatory challenges for clinical trials in the era of molecularly defined “Personalized therapies”

16.10 Session 4 “Bioinformatic approaches to big data analysis 17.40 and the clinical decision process”

FRIDAY 9 SEPTEMBER 2016 09.30

Session 5 “DEBATE: Impact on health care systems, a multi stakeholder societal challenge for research, pharma and patients”

10.30

Coffee Break

11.00 12.30

Session 6 “Horizons: Biomarker Signatures Beyond NGS. A bird’s-eye-view of the future of biomarkers on guiding drug development”

For further information, please contact: IBCD Secretariat EORTC Avenue E. Mounier 83 1200 Brussels, Belgium www.eortc.org/ibcd • [email protected]